Synchron raises $200 million for Stentrode platform commercialisation
US-based company Synchron secured $200 million in a Series D funding round to advance the commercial rollout of its Stentrode brain-computer interface (BCI) platform and support the development of next-generation interfaces.
Investment round details
Double Point Ventures led the funding round with participation from ARCH Ventures, Bezos Expeditions, Khosla Ventures, METIS, and NTI. New investors joining this round include:
- Australian National Reconstruction Fund (NRF)
- Qatar Investment Authority (QIA)
- T.Rx Capital
- K5 Global
- IQT
- Protocol Labs
Use of funds and company plans
Synchron plans to use the funding to accelerate key clinical trials and expand its multidisciplinary team.
“We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis,” said Synchron founder and CEO Tom Oxley.
“This funding brings us closer to commercialising the Stentrode BCI platform, while accelerating development of a major breakthrough in the field – a next-generation, transcatheter high-channel whole-brain interface.”
Synchron aims to deliver innovative solutions that improve quality of life through advanced brain-computer technology.
Would you like the author summary to be more technical or simplified?